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Abstract
Objectives To examine mortality and revision rates among patients with
osteoarthritis undergoing hip arthroplasty and to compare these rates
between patients undergoing cemented or uncemented procedures and
to compare outcomes between men undergoing stemmed total hip
replacements and Birmingham hip resurfacing.
Design Cohort study.
Setting National Joint Registry.
Population About 275 000 patient records.
Main outcome measures Hip arthroplasty procedures were linked to
the time to any subsequent mortality or revision (implant failure). Flexible
parametric survival analysis methods were used to analyse time to
mortality and also time to revision. Comparisons between procedure
groups were adjusted for age, sex, American Society of Anesthesiologists
(ASA) grade, and complexity.
Results As there were large baseline differences in the characteristics
of patients receiving cemented, uncemented, or resurfacing procedures,
unadjusted comparisons are inappropriate. Multivariable survival analyses
identified a higher mortality rate for patients undergoing cemented
compared with uncemented total hip replacement (adjusted hazard ratio
1.11, 95% confidence interval 1.07 to 1.16); conversely, there was a
lower revision rate with cemented procedures (0.53, 0.50 to 0.57). These
translate to small predicted differences in population averaged absolute
survival probability at all time points. For example, compared with the
uncemented group, at eight years after surgery the predicted probability
of death in the cemented group was 0.013 higher (0.007 to 0.019) and
the predicted probability of revision was 0.015 lower (0.012 to 0.017).
In multivariable analyses restricted to men, there was a higher mortality
rate in the cemented group and the uncemented group compared with
the Birmingham hip resurfacing group. In terms of revision, the
Birmingham hip resurfacings had a similar revision rate to uncemented
total hip replacements. Both uncemented total hip replacements and
Birmingham hip resurfacings had a higher revision rate than cemented
total hip replacements.
Conclusions There is a small but significant increased risk of revision
with uncemented rather than cemented total hip replacement, and a
small but significant increased risk of death with cemented procedures.
It is not known whether these are causal relations or caused by residual
confounding. Compared with uncemented and cemented total hip
replacements, Birmingham hip resurfacing has a significantly lower risk
of death in men of all ages. Previously, only adjusted analyses of hip
implant revision rates have been used to recommend and justify use of
cheaper cemented total hip implants. Our investigations additionally
consider mortality rates and suggest a potentially higher mortality rate
with cemented total hip replacements, which merits further investigation.
Introduction
Sir John Charnley’s1 introduction of low friction total hip
replacement2 3 50 years ago revolutionised the treatment of hip
arthritis. Today, hundreds of combinations of stems and cups
are successfully used. The different systems, however, are
simply categorised by their mode of fixation as cemented or
uncemented implants.
In patients under the age of 55, total hip replacements have not
been such a success, and hip resurfacing was developed as a
conservative alternative. Several reports show better medium
term implant survival and hip function4 5 with resurfacing than
with replacement6 7 in these younger patients.8 9 Initially hip
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resurfacing was carried out in women as well, but reported
results were poor.10Data from the National Joint Registry shows
that the cumulative failure rate of Birmingham hip resurfacing
in women is 1% per year,11 which borders on the edge of
acceptability according to guidelines from the National Institute
for Health and Clinical Excellence (NICE). This has resulted
in reduced acceptance of this procedure in women. There are
therefore three classes of hip arthroplasty that have gained
widespread acceptance and use: cemented and uncemented total
hip replacement in men and women and hip resurfacing in men.
The appendix provides details of the hip replacement and hip
resurfacing techniques with x ray images.
The number of procedures for hip arthroplasty is increasing as
the size of the elderly population increases. The availability of
various devices, with their differing materials and design
features, makes it essential to monitor their safety and
efficacy.12 13 Towards this end, orthopaedic associations in many
countries14-18 have been advocating the establishment of national
arthroplasty registers to acquire and analyse data. The National
Joint Register of England and Wales19 is currently the world’s
largest dataset of arthroplasty procedures. This contains over
400 000 records of patients who underwent hip arthroplasty and
includes vital information such as age, sex, primary diagnosis,
and ASA grade (the American Society of Anesthesiologists
classification system20 for assessing the fitness of patients before
surgery, from grade 1 (fit and healthy) to grade 5 (expected to
die within 24 hours with or without an operation)), all of which
can influence implant revision and mortality rates. Although
information relating to other risk factors such as obesity and
smoking might not be specified in the register, this information
is indirectly captured through the ASA grading system, which
takes these into account.21 With excellent compliance in data
entry and linking of procedures to the hospital episode statistics
database in England and its equivalent in Wales (PEDW), the
National Joint Registry constitutes a powerful evidence base to
inform the decision making of clinicians, healthcare providers,
patients, and implant manufacturers.
The registry is already being used to make recommendations
for the choice of procedure on the basis of implant survival
alone. That is, just analyses examining the time from primary
surgery until a revision hip replacement. In contrast, comparison
of mortality rates has received little attention. In its 2011 annual
report,19 the registry provided unadjusted and adjusted results
comparing revision rates for prosthesis type and bearing surface.
Only unadjusted comparisons of mortality rates were provided,
and adjusted analyses to control for differences in baseline
characteristics were not considered. In relation to unadjusted
death rates, they state that “the highest death rates were among
the cemented group and the lowest were among the resurfacing
group, reflecting the age distribution of these groups.” This
statement, however, does not recognise that there might be a
genuine difference in mortality rates between groups, even after
adjustment for age. Furthermore, the report does not calculate
absolute differences (such as in percentage revised at particular
times) between groups but rather presents results separately for
each group. It also says that “overlapping 95% confidence
intervals mean that differences are not statistically significant”;
this is not correct, as significant differences between groups can
still occur even when confidence intervals for each group
overlap.22 Thus it is clear that the report is an incomplete
summary of the current evidence.
Results from the National Joint Registry suggest significant
differences in implant survival between cemented and
uncemented total hip replacement and hip resurfacing, leading
the registry to conclude that “resurfacing has a higher revision
rate than stemmed total hip replacement regardless of brand.”19
They also recommend that in patients aged over 70, cemented
total hip replacements have the best revision rates and, being
the cheapest available option, these should be the preferred
choice unless good clinical reasons indicate otherwise. The
current NICE guidelines on total hip replacement also
recommend that cemented prostheses have better long term
viability and state that there are no data to support the use of
generally more costly uncemented and hybrid prostheses for
primary total hip replacement.23 Neither NICE nor the National
Joint Registry offer quantified advice on the relative safety in
terms of mortality rates with these different classes of device.
We examined this issue using the National Joint Registry’s
database to examine mortality and revision rates among patients
with osteoarthritis undergoing hip arthroplasty and to compare
these rates for the cemented, uncemented, and hip resurfacing
procedures. Furthermore, as current mortality comparisons from
the registry are based primarily on unadjusted results, we
produced adjusted results (including differences in absolute
survival probabilities) to allow a fairer comparison after
accounting for available potential confounding factors.
Methods
Primary and secondary objectives
Our primary objective was to determine whether there are any
differences in the mortality and revision rates over time between
patients with osteoarthritis undergoing cemented and
uncemented hip replacement surgery. Secondary objectives
were to compare mortality and revision rates for cemented and
uncemented procedures in each ASA grade separately and to
compare mortality rates and revision rates for cemented and
uncemented procedures and Birmingham hip resurfacing in all
men (as this is used predominately in men alone, as explained
above) and then in men aged under 55 (the group at highest risk
of implant failure with conventional arthroplasty).14
Obtaining data and exclusions
In August 2011, the National Joint Registry provided us up to
date raw patient level data without prior condition or prejudice.
This information included linkage of the National Joint Registry
dataset to the hospital episode statistics dataset (PEDW in
Wales) providing further information on time of any subsequent
revision and time of subsequent death if it occurred. Out of 423
287 hip arthroplasty procedures in the dataset, we removed
records of 14 281 hips for which the primary procedure was not
identified and 37 309 patients with a diagnosis other than
primary osteoarthritis. We also excluded records of all patients
who received a “hybrid” hip replacement as these use a variable
combination of cemented and uncemented fixation methods.
In its 2011 annual report the National Joint Registry showed
that the results of metal-on-metal total hip replacements are
highly design specific and that failure rates of some brands,
such as the ASR XL, are unacceptably high.19 The results of
these poorly performing designs, however, continue to
contaminate the data and the results on the registry. In view of
this, the report19 recommends the separation of metal-on-metal
total hip replacements from the remaining total hip replacements
and the analysis of them as a different class to the cemented and
uncemented groups. In keeping with that, we considered it
appropriate to exclude all 13 833 large diameter metal-on-metal
procedures.
The National Joint Registry data19 and the Australian Register24
show that the results of resurfacing are highly implant specific.
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Birmingham hip resurfacing predominates in worldwide use
and is the only device with 10 year registry follow-up24 and a
10A UK ODEP (Orthopaedic Data Evaluation Panel) rating).25
As our secondary analyses were to just compare Birmingham
hip resurfacing with cemented and uncemented total hip
replacements, we excluded all non-Birmingham hip resurfacings.
The dataset obtained from the National Joint Registry contained
duplicate entries for patients who underwent hip
replacement/resurfacing of both hips on the same date. We
removed the duplicate entry for these patients and created a
“both sides” variable to identify these patients from those who
underwent a single hip operation. We entirely excluded any
patient who had both hips replaced on the same date but
underwent a different procedure on each side.
We excluded 11 patients with missing data for age, sex, or ASA
grade. As these represented a tiny proportion of the total number
of patients, more sophisticated methods (such as multiple
imputation) for dealing with missing data were considered
unnecessary. This left a final total of 283 365 patients available
for analysis (154 996 receiving cemented total hip replacements,
120 017 receiving uncemented total hip replacements, and 8352
receiving Birmingham hip resurfacing).
Summarising baseline data
We summarised baseline characteristics of patients and
follow-up information (such as number censored and number
of deaths) for the dataset as a whole as well as by type of
procedure. We reported mean, standard deviation, median,
interquartile range, and the minimum and maximum values for
continuous variables, and total numbers and proportions for
categorical variables.
Statistical analysis
Primary objectives
For each patient in the dataset, their date of primary surgery and
their length of follow-up or time to end date (revision or death)
were available. As each of our two outcomes of interest were
time to event (that is, time to mortality and time to revision),
we used survival analysis methods to compare the cemented
and uncemented types of arthroplasty with potential adjustment
for five other variables (covariates) available in the database:
sex, age at primary surgery (in years), ASA grade before the
operation (1-5), complexity of procedure (either “primary” or
“complex primary”), and “both sides” replaced (either yes or
no).
Separate survival models were fitted for time to death and time
to revision. When analysing time to death, we censored those
patients alive or revised at the end of their follow-up; follow-up
information after revision was not available in the database.
Thus our inferences about, and comparisons of, mortality rates
at any time relate to patients without a revision before that time.
Similarly, when analysing time to revision we censored those
patients alive without revision or dead at the end of their
follow-up. Thus our inferences about, and comparisons of,
revision rates at any time relate to patients who are not already
dead at that time.
We used the Royston-Parmar method for our survival
modelling26 to obtain both unadjusted and adjusted results for
each covariate, with the “stpm2” command within the Stata
statistical software package.27 28 These models are flexible
parametric models that have advantages over Cox regression29
as the baseline cumulative hazard function is explicitly modelled
with restricted cubic splines. This allows hazard ratios to be
calculated, as the Cox model does, but additionally enables
absolute effects to be estimated (such as mortality rate per 1000
person years at time t and probability of survival at time t). The
hazard ratios estimated with this approach were similar to those
obtained through fitting a Cox regression model. We assumed
that the hazard ratio was a constant over time for each variable
as there was no indication to the contrary when we checked
“log-log” plots (in which log(−log(S(t)) is plotted against time,
where S(t) is the probability of not having the event up until at
least time t).
When modelling the baseline hazard in each Royston-Parmar
model, we tested different numbers of knots (which control the
number of different splines being used and where they connect)
and five knots were sufficient for the data. The multivariable
(adjusted) model was fitted with a backward stepwise selection
approach, which included type of procedure by default and any
other variables that were significant (as conservatively defined
by P<0.1). Age was included as a continuous variable and
modelled linearly.
Using the estimates from the multivariable model, we plotted
adjusted survival curves by predicting the population averaged
survival curve for each procedure. Essentially, a predicted
survival curve was obtained for each person in the database and
all the survival curves were averaged. Unlike Kaplan-Meier
curves, which are unadjusted, these survival curves allow a
fairer comparison of survival probabilities across procedures
after adjustment for other potential confounding covariates. We
thus used them to calculate and graphically display the
difference in the predicted population averaged survival
probabilities during the whole follow-up period. At any time
point, the difference in these survival probabilities can be used
to calculate the number needed (n) to change procedures to save
one event (n=1/difference in survival probability). In the results
presented below we calculate n at six or eight years for
illustration, as these times are toward the end of the follow-up
period.
Secondary objectives
To assess differences between surgery procedures in each ASA
grade separately, we refitted the multivariable Royston-Parmar
model (excluding ASA grade) for each of the grades separately,
and estimated the differences between cemented and uncemented
groups for each.
In the examination of Birmingham hip resurfacing compared
with cemented and uncemented procedures, we included only
men and thus refitted the multivariable model excluding the sex
covariate, but with no adjustment required for sex, and an
adjusted survival curve estimated for each of the three surgery
procedures. This was then repeated for just men aged under 55.
Results
In the dataset, between April 2003 and July 2011 a total of 154
996 patients received cemented hip replacement surgery and
120 017 patients received uncemented hip replacement surgery.
The median follow up time was 3.6 years in the cemented group
(range 0.001-9.7 years) and 2.6 years in the uncemented group
(0.001-8.6 years). During follow-up, 11 745 (7.6%) patients
died and 1589 (1.0%) had a revision in the cemented group
compared with 3728 (3.1%) and 1917 (1.6%), respectively, in
the uncemented group.
Table 1⇓ shows that baseline characteristics were not balanced
between the cemented and uncemented groups. In the cemented
group people were on average almost 7 years older. In the
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uncemented group there was a higher proportion of men (42.1%
v 34.5%), a higher proportion with ASA grade 1 (20.2% v
14.4%), and a lower proportion were considered as complex
(0.7% v 8.5%).
Primary analyses
Mortality
The Royston-Parmar model for mortality as the endpoint, with
procedure type as the only variable, gave an unadjusted hazard
ratio of 1.83 (95% confidence interval 1.76 to 1.90), suggesting
a higher mortality rate for cemented than uncemented
procedures. Because of the imbalance in baseline characteristics
between the groups, however, such unadjusted results are subject
to potential confounding.
Multivariable analysis showed that procedure type, age, sex,
ASA grade, and complexity of procedure were all significant
and were thus included in the final model. The “both sides”
variable, however, was not important. The adjusted hazard ratio
estimates from themodel are smaller than the unadjusted results,
but still suggest that the mortality rate is 1.11 (1.07 to 1.16)
times higher in the cemented group than in the uncemented
group (table 2⇓). This significant comparison relates to any time
point and to patients without a revision before that time. For
the other variables, the results suggest the mortality rate
increases with increasing age, generally increases as ASA grade
increases, is higher for men than women, and is higher for those
considered a “complex primary” procedure.
Figure 1⇓ shows the predicted population averaged survival
curves for cemented and uncemented procedures, with
adjustment for differences in age, sex, ASA grade, and
complexity. This shows a significant but small difference in the
probability of survival between the cemented and uncemented
groups. For example, at eight years after surgery the probability
of being alive was 0.013 higher (0.007 to 0.019) in the
uncemented group than in the cemented group for patients with
no revision before this time. At earlier times, the difference is
even smaller. This suggests that, in a hypothetical scenario in
which no patients undergo a revision by eight years, 77 patients
(53 to 143) need to be treated with an uncemented rather than
cemented procedure to result in one less death by eight years.
Revision
For revision as the endpoint, the unadjusted hazard ratio was
0.53 (0.50 to 0.57), suggesting a lower revision rate for cemented
than uncemented. Multivariable analysis showed that procedure
type, age, sex, and ASA grade were all significant and were
thus included in the final model, but not complexity of procedure
or the “both sides” variable. The adjusted hazard ratio estimates
from the model suggest that, at any time point, the revision rate
is 0.58 (0.54 to 0.62) times lower in the cemented group than
in the uncemented group (table 3⇓); this is similar to the
unadjusted result.
As for mortality, the impact of this hazard ratio can be translated
to the absolute probability scale by considering the adjusted
survival curve (fig 1), which shows the probability of not having
a revision for each procedure group over time for patients who
had not died previously. At any time, the curve shows only
small differences in this probability between groups—for
example, at eight years the probability of a revision is increased
by only 0.015 (0.012 to 0.017) in the uncemented group. This
suggests that, in a hypothetical scenario in which no patients
have died by eight years, 67 patients (58 to 84) need to be treated
with a cemented rather than uncemented procedure to result in
one less revision by eight years.
Secondary analyses
Mortality and revision rates for each ASA grade
separately
We examined mortality rates separately for each ASA grade,
with adjustment made for age, sex, and complexity of procedure.
There were too few patients in ASA grade 5 for the model to
be fitted in this subgroup. The adjusted hazard ratio comparing
cemented and uncemented procedures was significant for ASA
grade 2 (hazard ratio 1.15, 1.10 to 1.21) and ASA grade 4
patients (1.37, 1.03 to 1.83), indicating the cemented procedure
is associated with an increased mortality rate. There was no
significant effect for grade 1 (0.99, 0.88 to 1.11) or grade 3
(1.04, 0.96 to 1.12) patients.
Revision rates were adjusted for age and sex but not for
complexity of procedure as it was not significant. There was a
significant difference in revision rates between cemented and
uncemented procedures in grade 1 (hazard ratio 0.61, 0.51 to
0.72), grade 2 (0.60, 0.55 to 0.66), and grade 3 (0.46, 0.38 to
0.55), suggesting a lower hazard of revision for patients who
received the cemented procedure comparedwith the uncemented
procedure. Models could not be fitted for ASA grade 4 or 5
because of the small patient numbers in these subgroups.
Birmingham hip resurfacing in all men
We compared mortality and revision rates in all men for
cemented, uncemented, and Birmingham hip resurfacing
procedures. There were again baseline differences between
groups: the men undergoing Birmingham hip resurfacing men
were younger and a higher proportion were ASA grade 1
(47.9%) and ASA grade 2 (48.9%) (table 4⇓). Multivariable
analysis including the significant variables of age, ASA grade,
and complexity of procedure, estimated that the hazard of death
was 1.64 (1.33 to 2.02) times higher for the cemented group
and 1.47 (1.19 to 1.82) times higher for the uncemented group
when compared with Birmingham hip resurfacing (table 5⇓).
The population averaged survival curve shows that the highest
probability of survival is seen for the Birmingham hip
resurfacing group, with 92.1% (90.6% to 93.6%) predicted to
be alive at six years, conditional on patients not undergoing
revision before this time (fig 2⇓). At six years, the probability
of survival for patients who have not undergone revision is
0.044 (0.029 to 0.060) higher in those undergoing Birmingham
hip resurfacing rather than cemented procedures. This suggests
that, in a hypothetical scenario in which no patients undergo
revision by six years, 23 men (17 to 35) need to be treated with
Birmingham hip resurfacing rather than a cemented procedure
to result in one less death by six years.
For revision, the cemented group performs best with a hazard
ratio of 0.65 (0.54 to 0.79) compared with Birmingham hip
resurfacing. There was no significant difference between
Birmingham hip resurfacing and uncemented procedures, with
a hazard ratio of 1.04 (0.87 to 1.25; P=0.657) (table 6⇓). The
adjusted survival curve for revision (fig 2⇓) shows that the men
in the cemented group have the highest probability of no revision
over time. At all times, however, the absolute differences in the
predicted population averaged probability of revision are small
between all groups.
Birmingham hip resurfacing in men aged under
55
In men under the age of 55 only, there were still baseline
differences between groups (table 7⇓). The adjusted survival
curve shows (fig 3⇓) that the differences in patient mortality
between those undergoing Birmingham hip resurfacing and
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cemented and uncemented total hip replacement remain, with
significantly higher predicted population averaged survival in
the Birmingham hip resurfacing group. For patients who have
not undergone revision at six years, the predicted probability
of being alive in the Birmingham hip resurfacing group is 0.018
higher (0.008 to 0.029) than in the cemented group and 0.013
higher (0.006 to 0.020) than in the uncemented group. There
were no significant differences between the groups for revision
rates (fig 3⇓), although this could reflect a low power.
Discussion
In addition to well known differences in revision rates, our
multivariable analyses showed significant differences in
mortality rates after different surgical procedures for hip
replacement. The lowest mortality rate was in men with
Birmingham hip resurfacing, followed by all patients with
uncemented total hip replacement, and with the highest rate in
all patients with cemented total hip replacement. The primary
endpoint of most arthroplasty registers originally was implant
survival. Effective linkage to other health related registers, such
as the National Joint Registry linkage to hospital episode
statistics (and the Welsh equivalent), now promises to widen
their scope to other endpoints. The database of over 400 000
entries for primary hip surgery in the registry offers a unique
opportunity to compare implant survival and mortality rates
between cemented and uncemented total hip replacement and
also to compare these procedures with Birmingham hip
resurfacing in men.
The strengths of our study are the large number of patients and
events in the National Joint Registry database linked to mortality
records from the hospital episode statistics (and the Welsh
equivalent) datasets; the ability to adjust for five potential
confounding factors (age, sex, complexity, ASA grade,
bilaterality); and the advanced statistical methods that allowed
us to calculate both relative effects (hazard ratios) and
differences in absolute survival probabilities, so that we could
produce adjusted (population averaged) survival curves.30
Based on comparisons of revision rates alone, the cemented
procedure is currently recommended. It is clear, however, that
with comparisons of unadjusted mortality rate, one should
actually recommend the uncemented procedure. The baseline
differences between cemented and uncemented groups clearly
show there is a selection mechanism being used to allocate
individuals to a particular procedure. For this reason, unadjusted
comparisons are not reasonable and should be abandoned.
Our study is an attempt to redress the balance with appropriate
adjustment for all the known confounding factors in the National
Joint Registry data and simultaneous estimation of differences
in implant survival and patient survival in the different classes
of devices.We used the flexible parametric method, which gives
the same results as a Cox regression but adjusts for confounding
factors and additionally models the underlying hazard of an
event over time.
Key results
Differences in mortality rate between cemented
and uncemented total hip replacement
In keeping with previous studies we excluded diagnoses other
than osteoarthritis,31 hybrid and reverse hybrid fixed total hip
replacement,32 and metal-on-metal total hip replacement19 to
clearly delineate the differences between cemented and
uncemented hip replacement. Unadjusted figures from the
National Joint Registry19 show estimated mortality rates of 0.4%
and 0.2% at 30 days, 0.8% and 0.5% at 90 days, and 21.8% and
12.3% at eight years in cemented and uncemented procedures,
respectively. These figures compare well with Medicare
information relating to 61 568 primary total hip replacements,
which showed a 90 day mortality rate of 0.97%,33 and a review
of 7478 uncemented total hip replacements from a specialist
centre, which reported overall 30 and 90 day mortality rates of
0.2% and 0.6%, respectively.34
A report based on the Australian and Norwegian registers35with
106 254 total hip replacements shows that there is an increase
in mortality in the first 26 postoperative days of 0.1% compared
with the baseline. The Danish register showed that the 30 day
mortality after a total hip replacement was higher than matched
controls and the 90 day mortality was lower.36 Studies from
Norwegian and Finnish registers showed that compared with
the general population, total hip replacement was associated
with a higher mortality during the first 60 days and a lower
mortality during the subsequent 10 years.37 38 Another Finnish
study39 extending to 30 years confirmed the reduced mortality
in patients with total hip replacement in the first decade,
equalling the general population in the second decade, and
higher mortality than the general population during the third.39
The numbers in this study were relatively low compared with
those in the National Joint Registry.
The above reports do not show a direct comparison of mortality
rates between cemented and uncemented total hip replacement,
except the Norwegian study, which showed a lower mortality
(relative mortality rate ratio of 0.84) in patients with an
uncemented total hip replacement compared with cemented
procedure with high viscosity cement.37 In our large cohorts of
patients we found a significant difference in mortality between
cemented and uncemented total hip replacement after adjustment
for diagnosis, age, sex, complexity, and fitness based on ASA
grade. The unadjusted mortality rate ratio for cemented
compared with uncemented procedures is 1.83 (1.76 to 1.90).
After adjustment for the above variables the ratio is 1.11 (1.07
to 1.16), which is also significant (P<0.001). In a hypothetical
scenario in which no patients undergo revision by eight years,
the adjusted model results predict that 77 patients (53 to 143)
need to be treated with an uncemented rather than a cemented
procedure to attain one less death by eight years.
Implant survival differences between cemented
and uncemented total hip replacement
Most national arthroplasty registers, including the National Joint
Registry, show a benefit for implant survival with cemented
compared with uncemented total hip replacement. A recent
systematic review of registers showed that 10 year implant
survival of cemented total hip replacements ranges from 88%
in Finland to 95% in Norway,40 which is superior to the 10 year
survival of uncemented procedures, ranging from 80% in
Finland to 85% in Sweden. The unadjusted and adjusted hazard
ratios for implant survival in the present study for cemented
procedures comparedwith uncemented procedures are estimated
as 0.53 and 0.57, respectively, and are both significant. When
translated to the absolute probability scale the differences are
small. The predicted population averaged probability of revision
is estimated to increase by 0.015 in the uncemented group,
which—in a scenario in which there are no deaths—suggests
that 67 hips (58 to 84) need to be treated with cemented rather
than uncemented total hip replacement to reduce one revision
over eight years.
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Implant survival and mortality rate differences in
men
In a systematic review Santaguida et al showed that after total
joint arthroplasty, being male is associated with increased risk
of both implant revision and mortality.41 Younger men have an
increased risk of revision, while older men have an increased
risk of mortality. In short, younger men wear their hips out
prematurely and older men die early after hip replacement
compared with women.
Our analysis of the National Joint Registry data shows that,
among men of all ages without a revision by six years, the
unadjusted figures for six year patient survival and implant
survival are 85% and 98% in cemented procedures, 91% and
97% in uncemented procedures, and 98% and 97% in
Birmingham hip resurfacings, respectively. After adjustment
for all known risk factors, patient survival with Birmingham
hip resurfacing continues to be superior to survival in those with
uncemented total hip replacement, which in turn is superior to
those with cemented total hip replacement. Adjusted analyses
also indicate that implant survival in cemented total hip
replacement continues to be superior to uncemented total hip
replacement and Birmingham hip resurfacing. There is no
statistical evidence at any time point of a difference in implant
survival between uncemented total hip replacement and
Birmingham hip resurfacing.
Several national registers show that the risk of implant revision
is highest in young patients (variably defined in different studies,
under 60 in the Norwegian registry and under 55 in the Finnish
and Swedish registries), especially in young men in whom it is
increased threefold to fivefold.41 The 10 year Kaplan-Meier
survival ranged from 72% in Finland to 86% in Sweden in
younger patients (under 55) compared with 90% and 97% in
older patients (55 and above) in the same countries.40 A Finnish
register based study showed that survival of uncemented stems
is superior to that of cemented stems in patients aged under 55,
with aseptic loosening as the endpoint.42 The Swedish hip
arthroplasty register reported 10 year survival of 66%, 67%,
and 64% with cemented, uncemented, and hybrid total hip
replacement, respectively, in young men with osteoarthritis43
and therefore considered young patients with hip arthritis to be
the “supreme challenge” for hip replacement.44The Birmingham
hip resurfacing procedure was developed for this particular
cohort of young patients with osteoarthritis.45 Our results show
that at the six year stage there is no significant difference in
adjusted implant survival between the three classes of device,
though this could be because of low power, but the adjusted
mortality rate shows that Birmingham hip resurfacing
outperforms cemented and uncemented total hip replacement.
Two recent studies (postdating the original submission of this
article) have also used flexible parametric survival analysis to
interpret data from National Joint Registry. Smith et al
highlighted higher failure rates with stemmed metal-on-metal
hip replacements—that is, not resurfacings.46 We specifically
excluded this metal-on-metal group from our study. The same
investigators also assessed the risk of cancer in patients receiving
metal-on-metal stemmed hips, metal-on-metal resurfacings, and
other bearing stemmed total hips.47 They concluded “...our
models indicated that patients undergoing resurfacing procedures
were less likely than those with alternative bearings to get a
diagnosis of prostate cancer, haematological cancers, or any
cancer and had a lower risk of death.” This work supports the
findings of our more detailed analysis suggesting lower adjusted
mortality rates in patients undergoing resurfacing.
Limitations
There are limitations to our study. One of these is the potential
for unknown confounders that were not recorded in the database.
Registries by nature contain observational data with a potential
for bias at different levels. Adjustment for known confounding
factors was obtained with a flexible parametric survival analysis
including potential confounders as covariates. An alternative
approach to adjustment is to use propensity scores (for example,
where the propensity to be given cemented or uncemented is
first modelled and then each patient’s propensity score is
included as an adjustment covariate), but this is not necessarily
better at reducing confounding than our more standard
approach.48 Compared with unadjusted analyses, our adjusted
analyses reduced the estimated differences between groups both
in terms of mortality and implant survival but the potential for
other residual confounders cannot be ruled out. We included
the complexity covariate (defined as “primary” or “complex
primary” in the database) as an adjustment factor in our analyses
of mortality as it was significant. Indeed, it is possible that this
covariate is associated with another factor we have been unable
to adjust for.
Although the terms primary and complex primary were
introduced in the National Joint Registry forms in 2005, there
has never been a clear definition of these terms. It seems they
had not been included in the earlier version (2003) and have
subsequently been removed from the version currently used. If
the covariate had a significant effect on revision rates it could
have validated itself, but in our analysis it did not have a
significant association with revision rates (though it did have a
significant association with mortality rates). There is therefore
potential debate as to how it will have been routinely recorded
across different hospitals. The National Joint Registry itself has
not used it in their flexible parametric analysis. As complexity
was recorded for all patients in the database and given that it
was clearly imbalanced between groups, we considered it
important to adjust for it when necessary (for instance, in the
mortality rate analyses). If complexity is removed from the
model, the hazard ratio for mortality between cemented and
uncemented total hip replacement increases further from 1.11
(1.07 to 1.16) to 1.17 (1.13 to 1.22).
Secondly, although implant revision is a clearly definable
endpoint, it is not an exclusive surrogate marker of a failing
implant. A loose cemented hip in an elderly patient in poor
health is likely to be treated non-operatively either because the
patient is too ill to undergo revision surgery or simply prefers
to put up with the pain and limitation of function rather than
risk another major operation. It is more common to perform
revision surgery when needed for younger patients.42 The former
will be treated as a success and the latter a failure. Unrealistic
expectations in patients and ease of revision place different
thresholds for revision in different classes of implants.49
Therefore the place of revision focused survival analysis is being
challenged in orthopaedic literature.50 Outcome measures51 and
other markers of implant function need to be introduced.52
Thirdly, in the assessment of mortality, the cause of death was
not available and thus could not be summarised. Furthermore,
mortality data for patients having revisions are missing in the
National Joint Registry database we were provided with. Thus
our inferences about, and comparisons of, mortality rates at any
time point are specific to patients without a revision before that
time. We cannot therefore make any inferences about mortality
rates in patients with a revision. Similarly, our analyses of
revision rates censor patients who died without revision at their
time of death. Thus our inferences about, and comparisons of,
revision rates at any time point are specific to patients who have
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not died before that time. An alternative competing risks analysis
could be used to examine revision rates with dead unrevised
patients kept in the analysis (and thus not censored). This
approach is taken by the National Joint Registry19 and others53
and will lead to lower estimates of revision rates than our
analysis because they include people who have died, after which
they clearly will not be revised. We will consider such analyses
in further work, to make inferences about the predicted
probability of revision at particular times for all patients, some
of whom might have died previously. We have not done this
here because the available data force us to present mortality
rates conditional on being unrevised; so a direct contrast is to
present revision rates conditional on not being dead.
Furthermore, ASA grade can be a poor yardstick of general
health. None of the registers have a record of activity level. It
could be argued that even after adjustment for ASA grade, there
can be residual confounding, with the more active population
being selected for uncemented rather than cemented total hip
replacement. If increased activity level conferred longer life in
the uncemented group, that same activity level could have also
caused the higher failure rate in the uncemented group. When
analysing the same effect in young men we find a paradox. If
increased activity level confers a much higher life expectancy
in the Birmingham hip resurfacing group, one would expect the
higher activity to lead to an increased revision rate with
Birmingham hip resurfacing compared with total hip
replacement. The robust bearing with Birmingham hip
resurfacing, the large head with low risk of dislocation, and the
mechanically sound femoral reconstruction keeping the point
of fixation coincident with the point of loading, unlike a
stemmed total hip replacement, are some favourable design
features.
The follow-up of eight years in the current National Joint
Registry is also considered relatively short. Whether the
differences in mortality between the groups decrease with time
or whether they continue to diverge over a longer period remains
to be seen. With respect to implant revision, published data in
young patients show that while total hip replacement failures
follow a sustained pace54 in the longer term, more failures with
Birmingham hip resurfacing tend to occur in the early years
from femoral neck fractures, etc.55 Our analysis shows that up
to the six year stage, for men aged under 55 there is no
significant difference in National Joint Registry revision rates
between the three classes of device.Whether longer term results
will show that this trend continues or whether significant
differences develop later between the device classes, is not
known. It is regrettable that although eight year results are
currently available for total hip replacement on the National
Joint Registry, the entries for Birmingham hip resurfacing extend
only to six years even though such resurfacing has been
performed in England and Wales for over 14 years.
Finally, an alternative approach to analysis could consider the
time to either death or revision, whichever came sooner. A
multivariable analysis for this composite outcome gives an
adjusted hazard ratio that slightly favours the cemented
procedure (0.94, 95% confidence interval 0.91 to 0.97). This
approach, however, treats revision and death as equally
unwelcome, which is highly debatable. Furthermore, there was
evidence of non-proportional hazards in this analysis, indicating
that the hazard ratio is not constant over time. For such reasons,
and because death and revision are important clinical outcomes
on their own, we focused on comparisons for death and revision
separately in our investigations.
Epidemiological magnitude of the problem
The evidence in this analysis suggests there are differences
between the outcomes of cemented and uncemented total hip
replacements in terms of both revision and mortality rates. On
average across the population, our model predicts that
performing a cemented instead of an uncemented total hip
replacement results in an extra death once in every 77 (95%
confidence interval 53 to 143) procedures every eight years for
patients who do not undergo revision before this time;
conversely, the disadvantage of uncemented total hip
replacement is that an extra revision is predicted within eight
years for every 67 (58 to 84) procedures for patients alive at
this time. Secondary analyses in men showed that the lowest
death rate is associated with Birmingham hip resurfacing. By
performing a cemented total hip replacement instead of
resurfacing, our analysis predicts an extra death occurs within
six years for every 23 (17 to 35) operations.
Although the hazard ratios and differences in survival
probabilities for mortality between procedure types are small,
a large number of people currently undergo hip arthroplasty and
the number is increasing year on year. Therefore even small
differences, if they are genuine, indicate potentially large
numbers of avoidable deaths. For example, an estimated 1.2
million hip arthroplasties56 were performed worldwide in 2011
alone. If hypothetically 1.2million planned cemented procedures
were changed to uncemented procedures then, based on our
model estimates, there would be a predicted 15 584 (8392 to
22 641) fewer deaths by eight years for patients who had not
undergone revision by this time. As the baby-boomer generation
ages the number of arthroplasties has been progressively
increasing and therefore the number of potential avoidable
deaths could also progressively increase if cemented hips
continue to be used widely. If 40% of these 1.2 million are
assumed to be men then, based on our estimates, switching 0.48
million cemented procedures to Birmingham hip resurfacing
would lead to a predicted 20 869 fewer deaths (13 714 to 28
235) at six years for who had not undergone revision before this
time.
This aspect of higher mortality with cemented total hip
replacement has not been highlighted or investigated in detail
in the past. The numbers of preventable deaths from cemented
total hip replacement creates considerable public health interest.
The small increased mortality is not restricted to the early
postoperative period but continues to persist eight years after
the operation. This is a cause for concern and a reason for further
investigation. It is a priority to identify the reasons for the higher
observed mortality in cemented total hip replacements.
Recognising the fact that the consequences of death and revision
are not in the same league, the real question that needs to be
examined is to what extent is the observed higher death rate in
cemented total hip replacement a result of selection bias
(residual confounding) and to what extent it is a direct causal
effect of the cement and cementing process?
The potential for residual confounding is strong, given the
imbalances observed at baseline between groups, and the
National Joint Registry should consider recording additional
variables in the future to enable further adjustments for potential
confounding. For example, although our adjustment for ASA
grade will capture some of the comorbidities of individuals, it
would be better if more detailed recording of existing diseases,
conditions, and prognostic factors (such as smoking) were
available to allow further more direct adjustment for
confounding. Another suggestion that the difference in mortality
might not be genuine is the lack of a significant hazard ratio
within patients with ASA grades 1 and 3. Though there was a
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significant difference for grades 2 and 4, and most patients are
grade 2, one would expect a true causal factor to impact on all
types of patients but this was not observed. On the other hand,
one cannot rule out that cement might be genuinely increasing
the risk of death. If it is, then clearly it should be avoided as
there must be an underlying causal mechanism. Several
mechanisms might be suggested, though this of course is
speculative.
Although polymethylmethacrylate (PMMA) bone cement is
biocompatible, adverse cardiopulmonary effects57-62 have been
widely documented during and after the cementation period.
Modern cement techniques,63 including pressurisation, which
were developed to improve cement penetration and fixation can
exacerbate these events.64During the reaming and pressurisation
processes fat, marrow, air, particles of bone, cement, and
aggregates of platelets and fibrin are driven into the systemic
circulation57 with the potential for intraoperative and
postoperative embolic events and adult respiratory distress
syndrome. Embolic events have been found to correlate with
haemodynamic changes suggesting pulmonary embolism65 and
have been observed in over 90% of cases66 by transoesophageal
echocardiography. Furthermore about 10% of normal patients
have right to left shunt, giving the possibility of systemic
embolisation with unknown long term effects.67-69 In comparison,
the relative rarity of overt postoperative adult respiratory distress
syndrome in patients suggests that the embolic insult is usually
insufficient to cause important clinical symptoms immediately.
The persistence of increasedmortality over eight years, however,
raises the question of whether the embolisation has the potential
to reduce the normal respiratory reserve, making the patient
prone to succumb to minor respiratory diseases in the longer
term. A long term detrimental effect on other organ systems
from systemic embolisation could also explain the continuing
increased mortality.
We have had the opportunity of studying embolisation
intraoperatively after cemented total hip replacement and
Birmingham hip resurfacing using transoesophageal
echocardiography.70 The embolisation of echogenic material
into the right heart and lungs is markedly different with the two
different procedures. With Birmingham hip resurfacing, there
is momentary transient embolisation or no embolisation, whereas
with cemented total hip replacement there is profound
embolisation, which can persist for up to 20 minutes.⇓
Furthermore, the potential long term detrimental effects from
prolonged exposure to nephrotoxic agents such as gentamicin
from the bone cement cannot be ruled out, and this matter is
being actively investigated.
Direction of future research
Although much time and effort has been spent on research into
potential concerns about cancer, chromosome changes, and
metal ions with metal-on-metal bearings, it is ironic that the
lowest death rate of any hip arthroplasty on the National Joint
Registry is with metal-on-metal Birmingham hip resurfacing.
The question of why cemented total hip replacement is
associated with the highest death rate has not been adequately
researched.
Death is the simplest of all outcomes to measure, is well
documented and easily understood by the patient, and has
profound implications for the patient and his or her family, but
yet it is largely neglected by registries. Thus far, we have been
comfortable to ignore it because patients with total hip
replacement survive as long as or longer than non-operated
controls, the differences between cemented and uncemented
implants are small, any perceived differences have been
explained away by different characteristics of patients at
baseline, and the raw data have not previously been made
available for analysis.
The registers should be congratulated on the collection of data
but need to go further to make detailed recording of all relevant
information to allow accurate analysis and conclusions. This
must include measurement of the activity levels and any other
potential confounding factors.
The evidence of lower risk of death after hip resurfacing
independently arrived at by two research groups (our present
study and Smith et al47) working on this large database should
reassure patients with metal-on-metal resurfacing that this
procedure is at least as safe and at best safer than total hip
replacement in terms of overall mortality.
More work is necessary to determine whether the higher
mortality rate after cemented total hip replacement is caused by
the cementing procedure or if this is because of other as yet
unknown confounding factors such as differences in activity
level between the groups.
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Tables
Table 1| Summary of baseline characteristics and follow-up data by procedure type in patients undergoing cemented or uncemented hip
arthroplasty. Figures are numbers (percentage) unless stated otherwise
Overall (n=275 013)Uncemented (n=120 017)Cemented (n=154 996)
Baseline characteristics
Age (years):
70.4 (9.9)66.7 (10.1)73.2 (8.7)Mean (SD)
71.267.073.8Median
64.2-77.360.5-73.768.0-79.2Interquartile range
15.4-106.215.4-106.215.9-103.4Range
Sex:
103 938 (37.8)50 529 (42.1)53 409 (34.5)Men
171 075 (62.2)69 488 (57.9)101 587 (65.5)Women
ASA (American Society of Anesthesiologists) grade:
46 612 (17.0)24 276 (20.2)22 336 (14.4)1
189 499 (68.9)82 104 (68.4)107 395 (69.3)2
37 520 (13.6)13 151 (11.0)24 369 (15.7)3
1308 (0.5)456 (0.4)852 (0.6)4
74 (0.03)30 (0.02)44 (0.03)5
Surgery
Approach:
914 (0.4)429 (0.4)485 (0.3)Anterior
19 384 (7.5)7161 (6.1)12 223 (8.6)Anterolateral
63 200 (24.3)28 834 (24.7)34 366 (24.1)Hardinge
44 458 (17.1)14 321 (12.3)30 137 (21.1)Lateral (incl Hardinge)
120 941 (46.6)61 086 (52.3)59 855 (41.9)Posterior
1260 (0.5)96 (0.1)1164 (0.8)Trochanteric osteotomy
9609 (3.7)4989 (4.3)4620 (3.2)Other
15 247 (5.5)3101 (2.6)12 146 (7.8)Missing
Complexity of procedure:
260 997 (94.9)119 172 (99.3)141 825 (91.5)Primary
14 016 (5.1)845 (0.7)13 171 (8.5)Complex primary
Both sides:
274 295 (99.7)119 497 (99.6)154 798 (99.9)No
718 (0.3)520 (0.4)198 (0.1)Yes
Follow-up
Endpoint:
15 473 (5.6)3728 (3.1)11 745 (7.6)Death
3506 (1.3)1917 (1.6)1589 (1.0)Revision
256 034 (93.1)114 372 (95.3)141 662 (91.4)Unrevised
858 512323 477535 035Total length of follow-up, person years
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Table 2| Adjusted hazard ratios from multivariable analysis with mortality as endpoint in patients undergoing total hip replacement
P valueHazard ratio (95% CI)Variable
Surgery:
——Uncemented
<0.0011.11 (1.07 to 1.16)Cemented
<0.0011.09 (1.09 to 1.09)Age (years)
ASA (American Society of Anesthesiologists) grade:
——1
<0.0011.19 (1.13 to 1.26)2
<0.0012.15 (2.03 to 2.28)3
<0.0013.52 (3.09 to 4.00)4
<0.0012.94 (1.70 to 5.07)5
Sex:
——Women
<0.0011.54 (1.49 to 1.59)Men
Complexity:
——Primary
<0.0011.40 (1.33 to 1.46)Complex primary
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Table 3| Adjusted hazard ratios from multivariable analysis with revision as endpoint in patients undergoing total hip replacement
P valueHazard ratio (95% CI)Variable
Surgery:
——Uncemented
<0.0010.58 (0.54 to 0.62)Cemented
<0.0010.99 (0.98 to 0.99)Age (years)
ASA (American Society of Anesthesiologists) grade:
——1
0.0641.09 (1.00 to 1.19)2
<0.0011.38 (1.22 to 1.55)3
0.1510.60 (0.30 to 1.20)4
——5*
Sex:
——Female
<0.0011.15 (1.08 to 1.23)Male
*Not estimable because there were too few patients and events in this group
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Table 4| Summary of baseline characteristics and follow-up information by procedure type in men undergoing hip arthroplasty, including
Birmingham hip resurfacing. Figures are numbers (percentage) unless stated otherwise
Cemented (n=53 409)Uncemented (n=50 529)Birmingham hip resurfacing (n=8352)
Baseline characteristics
Age (years):
72.3 (8.6)66.2 (9.9)55.9 (8.6)Mean (SD)
72.966.756.6Median
67.2-8.160.3-73.150.4-61.9Interquartile range
18.1-101.717.1-98.819.0-85.0Range
ASA (American Society of Anesthesiologists) grade:
8246 (15.4)10 761 (21.3)3999 (47.9)1
35 838 (67.1)33 594 (66.5)4087 (48.9)2
8947 (16.8)5918 (11.7)256 (3.1)3
360 (0. 7)246 (0.5)8 (0.1)4
18 (0.03)10 (0.02)2 (0.02)5
Procedure type:
48 743 (91.3)50 176 (99.3)8262 (98.9)Primary
4666 (8.7)353 (0.7)90 (1.1)Complex primary
Both sides:
53 319 (99.8)50 304 (99.6)8297 (99.3)No
90 (0.2)225 (0.5)55 (0.7)Yes
Follow-up
Endpoint:
4821 (9.0)1872 (3.7)93 (1.1)Death
645 (1.2)830 (1.6)159 (1.9)Revision
47 943 (89.8)47 827 (94.7)8100 (97.0)Unrevised
183 101134 70227 961Total length of follow-up, person years
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Table 5| Adjusted hazard ratios from multivariable analysis of men undergoing hip arthroplasty, including those undergoing Birmingham
hip resurfacing, with mortality as endpoint
P valueHazard ratio (95% CI)Variable
Surgery:
——Birmingham hip resurfacing
<0.0011.64 (1.33 to 2.02)Cemented
<0.0011.47 (1.19 to 1.82)Uncemented
<0.0011.09 (1.09 to 1.09)Age (years)
ASA (American Society of Anesthesiologists) grade:
——1
<0.0011.17 (1.09 to 1.26)2
<0.0012.14 (1.97 to 2.33)3
<0.0013.58 (2.98 to 4.30)4
0.5320.54 (0.08 to 3.80)5
Complexity:
——Primary
<0.0011.31 (1.22 to 1.41)Complex primary
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Table 6| Adjusted hazard ratios from multivariable analysis of men undergoing hip arthroplasty, including those undergoing Birmingham
hip resurfacing, with revision as endpoint
P valueHazard ratio (95% CI)
Surgery:
——Birmingham hip resurfacing
<0.0010.65 (0.54 to 0.79)Cemented
0.6571.04 (0.87 to 1.25)Uncemented
0.0911.00 (0.99 to 1.00)Age (years)
ASA (American Society of Anesthesiologists) grade:
——1
0.1531.10 (0.97 to 1.24)2
0.0151.24 (1.04 to 1.48)3
0.2200.54 (0.20 to 1.45)4
——5*
*Not estimable because too few patients and events in this group
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Table 7| Summary of baseline characteristics and follow-up information by procedure type in men aged under 55. Figures are numbers
(percentage) unless stated otherwise
Cemented (n=1730)Uncemented (n=6193)Birmingham hip resurfacing (n=3560)
Baseline characteristics
Age (years):
49.1 (5.9)48.5 (6.1)47.9 (5.5)Mean (SD)
51.050.349.2Median
46.7-53.445.8-53.044.7-52.3Interquartile range
18.10-55.017.1-55.019.0-55.0Range
ASA (American Society of Anesthesiologists) grade:
692 (40.0)2595 (41.9)2077 (58.3)1
925 (53.5)3225 (52.1)1421 (39.9)2
108 (6.2)360 (5.8)59 (1.7)3
4 (0.2)12 (0.2)2 (0.1)4
1 (0.1)1 (0.02)1 (0.03)5
Procedure type:
1525 (88.2)6119 (98.8)3511 (98.6)Primary
205 (11.9)74 (1.2)49 (1.4)Complex primary
Both sides:
1716 (99.2)6143 (99.2)3531 (99.2)No
14 (0.2)50 (0.8)29 (0.8)Yes
Follow-up
Endpoint:
32 (1.9)56 (0.9)10 (0.3)Death
28 (1.6)107 (1.7)60 (1.7)Revision
1670 (96.5)6030 (97.4)3490 (98.0)Unrevised
599115 88611 637Total length of follow-up, person years
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Figures
Fig 1 Population averaged (adjusted) survival curves (with 95% confidence intervals shown by dashed lines) for cemented
versus uncemented with mortality or revision as endpoint
Fig 2 Population averaged (adjusted) survival curves (with 95% confidence intervals shown by dashed lines) for men
comparing cemented, uncemented, and Birmingham hip resurfacing patients, with mortality or revision as endpoint
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Fig 3 Population averaged (adjusted) survival curves for men aged under 55 comparing cemented, uncemented, and
Birmingham hip resurfacing patients, with mortality or revision as endpoint
Fig 4 Transoesophageal echocardiogram in patient after cemented total hip replacement, showing fat and marrow echogenic
material in right atrium and right ventricle. No echogenic material in left atrium or left ventricle, indicating that debris has
been filtered in pulmonary vasculature
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